Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enterprise Products Partners

Micron Technology

Newell Brands

Omnicom Group

Ralph Lauren

Southern Company

AT&T

Walgreens

Wells Fargo

Exxon Mobil

It might seem odd on Main Street that the S&P 500 has managed to recapture all its losses after the panic selling seen in February and March.

11 Blue Chip Stocks That Refuse to Rally With the Market’s All-Time Highs

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Aug. 31, 2020 /PRNewswire/ -- Mylan N.V.

Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes

HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2020 /PRNewswire/ -- Mylan N.V.

Mylan Initiates Voluntary Nationwide Recall of Four Lots of Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP Due to Carton Label Mix-Up

Los Angeles, California--(Newsfile Corp. - August 25, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 24, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 /PRNewswire/ -- Mylan N.V.

Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera®

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V.

ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action - MYL

Goodwill and intangibles form $20.48 billion of Mylan’s $30.16 billion balance sheet. The company owes about $12 billion in long-term debt.

Mylan: Treating Debt And Intangibles

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the “Class Period”), of the important August 25, 2020 lead plaintiff deadline in securities class action.

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYL

Mylan N.V. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript

Mylan, Inc. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript

Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.

Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

Generic Drugs And Tensions With China: The Case For Mylan

Mylan (MYL) delivered earnings and revenue surprises of 16.84% and 1.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Surpasses Q2 Earnings and Revenue Estimates

Mylan N.V. MYL, +3.55% said Thursday it had net income of $39.4 million, or 8 cents a share, in the second quarter, after a loss of $168.5 million, or 33 cents a share, in the year-earlier period.

Mylan swings to profit as sales fall slightly short of estimates

Mylan NV reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.

Mylan posts quarterly profit compared to year-earlier loss

HERTFORDSHIRE, England and PITTSBURGH, Aug. 6, 2020 /PRNewswire/ -- Mylan N.V.

Mylan Reports Strong Second Quarter and First Half 2020 Results and Updates 2020 Guidance

Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mylan (MYL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.

Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Mylan (MYL) Could Beat Earnings Estimates Again

HERTFORDSHIRE, England and PITTSBURGH, July 22, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2020 financial results on Thurs.

Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020

NEW YORK, July 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the "Class Period"), of the important August 25, 2020 lead plaintiff deadline.

ROSEN, A TOP RANKED INVESTOR FIRM, Reminds Mylan N.V. Investors of Important August 25 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MYL

News for Mylan Stock (MYL)